Principal Financial Group Inc Point Biopharma Global Inc. Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 02, 2023	BUY	$6.67 - $9.71 $30,228 - $44,005	4,532 Added 17.79%	30,000 $200,000
Q2 2023 Aug 07, 2023	BUY	$6.86 - $10.86 $2,901 - $4,593	423 Added 1.69%	25,468 $230,000
Q1 2023 May 09, 2023	SELL	$6.78 - $8.1 $11,275 - $13,470	-1,663 Reduced 6.23%	25,045 $182,000
Q4 2022 Feb 09, 2023	BUY	$5.72 - $9.78 $92,149 - $157,555	16,110 Added 152.01%	26,708 $194,000
Q3 2022 Nov 09, 2022	SELL	$7.24 - $10.31 $3,229 - $4,598	-446 Reduced 4.04%	10,598 $82,000
Q2 2022 Aug 10, 2022	BUY	$5.6 - $9.5 $61,846 - $104,918	11,044 New	11,044 $75,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.